Liver metastases: Microenvironments and ex-vivo models

Experimental Biology and Medicine

Volumn 241, Issue 15, 2016, Pages 1639-1652

  Clark, Amanda M ^a   Ma, Bo ^a   Taylor, D Lansing ^a,b,c,d   Griffith, Linda ^e   Wells, Alan ^a,b,c,f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of Pittsburgh   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e Massachusetts Institute of Technology   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

hepatic niche; Liver metastasis; metastatic models; microphysiological; tumor microenvironment

Indexed keywords

CD31 ANTIGEN; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; PROTEINASE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; DOWN REGULATION; EX VIVO STUDY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KUPFFER CELL; LIVER CELL; LIVER METASTASIS; MOUSE; NONHUMAN; SEX DIFFERENCE; STELLATE CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; BIOMIMETICS; HEPATIC STELLATE CELL; LIVER; METASTASIS; PATHOLOGY; PHYSIOLOGY;

BIOMIMETICS; HEPATIC STELLATE CELLS; HUMANS; KUPFFER CELLS; LIVER; NEOPLASM METASTASIS; TUMOR MICROENVIRONMENT;

EID: 84983356809     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370216658144     Document Type: Article

References (126)

1. K.R.HessG.R.VaradhacharyS.H.TaylorW.WeiM.N.RaberR.LenziJ.L.Abbruzzese. Metastatic patterns in adenocarcinoma. Cancer2006; 106: 1624–33.
2. D.P.JaquesD.G.CoitE.S.CasperM.F.Brennan. Hepatic metastases from soft-tissue sarcoma. Ann Surg1995; 221: 392–7.
3. E.K.AmankwahA.P.ConleyD.R.Reed. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol2013; 5: 147–62.
4. S.W.RyuR.SawR.A.ScolyerM.CrawfordJ.F.ThompsonC.Sandroussi. Liver resection for metastatic melanoma: equivalent survival for cutaneous and ocular primaries. J Surg Oncol2013; 108: 129–35.
5. F.X.BoschJ.RibesM.DiazR.Cleries. Primary liver cancer: worldwide incidence and trends. Gastroenterology2004; 127: S5–S16.
6. S.EarlamC.GloverC.FordyD.BurkeT.G.Allen-Mersh. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol1996; 14: 171–5.
7. J.PickrenY.TsukadaW.LaneLiver metastases: Analysis of autopsy data. In: (eds). Liver metastases, Boston, MA: GK Hall Medical Publishers, 1982, pp. 2–18.
8. H.A.GilbertA.R.KaganB.L.HintzA.R.RaoH.NussbaumPatterns of metastases. In: (ed). Liver metastases, Boston, MA: GK Hall Medical Publishers, 1982, pp. 19–39.
9. Z.Kmiec. Cooperation of liver cells in health and disease. Adv Anat EmbryolCell Biol2001; 161: III–XIII, 1–151.
10. F.Vidal-VanaclochaArchitectural and functional aspects of the liver with implications for cancer metastasis. In: (ed). Liver metastasis: biology and clinical management, 1st ed. Netherlands: Springer, 2011, pp. 9–42.
11. C.L.ChafferR.A.Weinberg. A perspective on cancer cell metastasis. Science2011; 331: 1559–64.
12. R.KalluriR.A.Weinberg. The basics of epithelial-mesenchymal transition. J Clin Investig2009; 119: 1420–8.
13. M.A.Nieto. Epithelial plasticity: a common theme in embryonic and cancer cells. Science2013; 342: 1234850–1234850.
14. A.WellsC.YatesC.R.Shepard. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis2008; 25: 621–8.
15. N.P.GunasingheA.WellsE.W.ThompsonH.J.Hugo. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev2012; 31: 469–78.
16. A.WellsJ.GrahovacS.WheelerB.MaD.Lauffenburger. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci2013; 34: 283–9.
17. Y.ChaoQ.WuM.AcquafondataR.DhirA.Wells. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron2012; 5: 19–28.
18. U.H.WeidleF.BirzeleA.Kruger. Molecular targets and pathways involved in liver metastasis of colorectal cancer. Clin Exp Metastasis2015; 32: 623–35.
19. R.MaY.FengS.LinJ.ChenH.LinX.LiangH.ZhengX.Cai. Mechanisms involved in breast cancer liver metastasis. J Transl Med2015; 13: 64–64.
20. H.ShiJ.LiD.Fu. Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. J Cancer Res Clin Oncol2016; 142: 1137–61.
21. F.Vidal-Vanaclocha. The prometastatic microenvironment of the liver. Cancer Microenviron2008; 1: 113–29.
22. J.A.JoyceJ.W.Pollard. Microenvironmental regulation of metastasis. Nat Rev Cancer2009; 9: 239–52.
23. Y.KienastL.von BaumgartenM.FuhrmannW.E.KlinkertR.GoldbrunnerJ.HermsF.Winkler. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med2010; 16: 116–22.
24. K.J.LuzziI.C.MacDonaldE.E.SchmidtN.KerkvlietV.L.MorrisA.F.ChambersA.C.Groom. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol1998; 153: 865–73.
25. I.J.Fidler. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer2003; 3: 453–8.
26. D.E.Ingber. Can cancer be reversed by engineering the tumor microenvironment?Semin Cancer Biol2008; 18: 356–64.
27. S.A.BrooksH.J.Lomax-BrowneT.M.CarterC.E.KinchD.M.Hall. Molecular interactions in cancer cell metastasis. Acta Histochem2010; 112: 3–25.
28. F.Balkwill. Tumour necrosis factor and cancer. Nat Rev Cancer2009; 9: 361–71.
29. F.BraetK.NagatsumaM.SaitoL.SoonE.WisseT.Matsuura. The hepatic sinusoidal endothelial lining and colorectal liver metastases. World J Gastroenterol2007; 13: 821–5.
30. T.HehlgansK.Pfeffer. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology2005; 115: 1–20.
31. H.H.WangA.R.McIntoshB.B.HasinoffE.S.RectorN.AhmedD.M.NanceF.W.Orr. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res2000; 60: 5862–9.
32. H.YanagidaM.KaiboriH.YoshidaK.HabaraM.YamadaY.KamiyamaT.Okumura. Hepatic ischemia/reperfusion upregulates the susceptibility of hepatocytes to confer the induction of inducible nitric oxide synthase gene expression. Shock2006; 26: 162–8.
33. S.JansenM.AndriesK.VekemansH.VanbilloenA.VerbruggenM.Bollen. Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett2009; 284: 216–21.
34. C.B.AaronsO.BajenovaC.AndrewsS.HeydrickK.N.BushellK.L.ReedP.ThomasJ.M.BeckerA.F.Stucchi. Carcinoembryonic antigen-stimulated THP-1 macrophages activate endothelial cells and increase cell-cell adhesion of colorectal cancer cells. Clin Exp Metastasis2007; 24: 201–9.
35. P.AugusteL.FallavollitaN.WangJ.BurnierA.BikfalviP.Brodt. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol2007; 170: 1781–92.
36. A.GangopadhyayD.A.LazureP.Thomas. Adhesion of colorectal carcinoma cells to the endothelium is mediated by cytokines from CEA stimulated Kupffer cells. Clin Exp Metastasis1998; 16: 703–12.
37. A.M.KhatibP.AugusteL.FallavollitaN.WangA.SamaniM.KontogianneaS.MeterissianP.Brodt. Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol2005; 167: 749–59.
38. J.LaferriereF.HouleM.M.TaherK.ValerieJ.Huot. Transendothelial migration of colon carcinoma cells requires expression of E-selectin by endothelial cells and activation of stress-activated protein kinase-2 (SAPK2/p38) in the tumor cells. J Biol Chem2001; 276: 33762–72.
39. Arteta B, Lasuen N, Lopategi A, Sveinbjornsson B, Smedsrod B, Vidal-Vanaclocha F. Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antitumor immunity through interleukin-1-induced mannose receptor in mice. Hepatology 2010;51:2172–82
40. K.EnomotoY.NishikawaY.OmoriT.TokairinM.YoshidaN.OhiT.NishimuraY.YamamotoQ.Li. Cell biology and pathology of liver sinusoidal endothelial cells. Med Electron Microsc2004; 37: 208–15.
41. R.FridmanG.GiacconeT.KanemotoG.R.MartinA.F.GazdarJ.L.Mulshine. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci USA1990; 87: 6698–702.
42. S.PascoL.RamontF.X.MaquartJ.C.Monboisse. Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol/Hematol2004; 49: 221–33.
43. S.SchenkE.HintermannM.BilbanN.KoshikawaC.HojillaR.KhokhaV.Quaranta. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol2003; 161: 197–209.
44. S.SchenkV.Quaranta. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol2003; 13: 366–75.
45. C.S.SwindleK.T.TranT.D.JohnsonP.BanerjeeA.M.MayesL.GriffithA.Wells. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol2001; 154: 459–68.
46. J.GrahovacD.BeckerA.Wells. Melanoma cell invasiveness is promoted at least in part by the epidermal growth factor-like repeats of tenascin-C. J Invest Dermatol2013; 133: 210–20.
47. J.GrahovacA.Wells. Matrikine and matricellular regulators of EGF receptor signaling on cancer cell migration and invasion. Lab Invest2014; 94: 31–40.
48. M.RodriguesC.C.YatesA.NuschkeL.GriffithA.Wells. The matrikine tenascin-C protects multipotential stromal cells/mesenchymal stem cells from death cytokines such as FasL. Tissue Eng A2013; 19: 1972–83.
49. T.DeckerM.L.Lohmann-MatthesU.KarckT.PetersK.Decker. Comparative study of cytotoxicity, tumor necrosis factor, and prostaglandin release after stimulation of rat Kupffer cells, murine Kupffer cells, and murine inflammatory liver macrophages. J Leukoc Biol1989; 45: 139–46.
50. C.R.GardnerA.J.WassermanD.L.Laskin. Differential sensitivity of tumor targets to liver macrophage-mediated cytotoxicity. Cancer Res1987; 47: 6686–91.
51. C.R.GardnerA.J.WassermanD.L.Laskin. Liver macrophage-mediated cytotoxicity toward mastocytoma cells involves phagocytosis of tumor targets. Hepatology1991; 14: 318–24.
52. S.SekiY.HabuT.KawamuraK.TakedaH.DobashiT.OhkawaH.Hiraide. The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol Rev2000; 174: 35–46.
53. W.SuT.KitagawaT.ItoT.OyamaC.M.LeeY.K.KimH.Matsuda. Antitumor effect to IL-12 administration into the portal vein on murine liver metastasis. J Hepato-Biliary-Pancreatic Surg2002; 9: 503–10.
54. M.TimmersK.VekemansD.VermijlenK.AsosinghP.KuppenL.BouwensE.WisseF.Braet. Interactions between rat colon carcinoma cells and Kupffer cells during the onset of hepatic metastasis. Int J Cancer2004; 112: 793–802.
55. J.M.YinglingK.L.BlanchardJ.S.Sawyer. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov2004; 3: 1011–22.
56. L.G.BayonM.A.IzquierdoI.SirovichN.van RooijenR.H.BeelenS.Meijer. Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver. Hepatology1996; 23: 1224–31.
57. N.C.BirdD.MangnallA.W.Majeed. Biology of colorectal liver metastases: a review. J Surg Oncol2006; 94: 68–80.
58. S.W.WenE.I.AgerC.Christophi. Bimodal role of Kupffer cells during colorectal cancer liver metastasis. Cancer Biol Ther2013; 14: 606–13.
59. M.S.SosaP.BragadoJ.A.Aguirre-Ghiso. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer2014; 14: 611–22.
60. F.G.Giancotti. Mechanisms governing metastatic dormancy and reactivation. Cell2013; 155: 750–64.
61. C.M.GhajarH.PeinadoH.MoriI.R.MateiK.J.EvasonH.BrazierD.AlmeidaA.KollerK.A.HajjarD.Y.StainierE.I.ChenD.LydenM.J.Bissell. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol2013; 15: 807–17.
62. P.ThomasH.HayashiR.ZimmerR.A.Forse. Regulation of cytokine production in carcinoembryonic antigen stimulated Kupffer cells by beta-2 adrenergic receptors: implications for hepatic metastasis. Cancer Lett2004; 209: 251–7.
63. T.KnittelM.MehdeD.KoboldB.SaileC.DinterG.Ramadori. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol1999; 30: 48–60.
64. D.L.GordenB.FingletonH.C.CrawfordD.E.JansenM.LepageL.M.Matrisian. Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. Int J Cancer2007; 121: 495–500.
65. N.KangG.J.GoresV.H.Shah. Hepatic stellate cells: partners in crime for liver metastases?Hepatology2011; 54: 707–13.
66. E.OlasoA.SantistebanJ.BidaurrazagaA.M.GressnerJ.RosenbaumF.Vidal-Vanaclocha. Tumor-dependent activation of rodent hepatic stellate cells during experimental melanoma metastasis. Hepatology1997; 26: 634–42.
67. T.AmannF.BatailleT.SprussM.MuhlbauerE.GabeleJ.ScholmerichP.KieferA.K.BosserhoffC.Hellerbrand. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci2009; 100: 646–53.
68. A.MazzoccaR.CoppariR.De FrancoJ.Y.ChoT.A.LibermannM.PinzaniA.Toker. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res2005; 65: 4728–38.
69. H.OkabeT.BeppuH.HayashiT.IshikoT.MasudaR.OtaoH.HorladH.JonoM.UedaS.S.PhdY.AndoH.Baba. Hepatic stellate cells accelerate the malignant behavior of cholangiocarcinoma cells. Ann Surg Oncol2011; 18: 1175–84.
70. W.ZhaoL.ZhangZ.YinW.SuG.RenC.ZhouJ.YouJ.FanX.Wang. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer2011; 129: 2651–61.
71. S.ShimizuN.YamadaT.SawadaK.IkedaN.KawadaS.SekiK.KanedaK.Hirakawa. In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells. Jpn J Cancer Res2000; 91: 1285–95.
72. R.MatsusueH.KuboS.HisamoriK.OkoshiH.TakagiK.HidaK.NakanoA.ItamiK.KawadaS.NagayamaY.Sakai. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol2009; 16: 2645–53.
73. O.MussoN.TheretJ.P.CampionB.TurlinS.MilaniC.GrapponeB.Clement. In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis. J Hepatol1997; 26: 593–605.
74. N.TheretO.MussoJ.P.CampionB.TurlinO.LorealA.L’Helgoualc’hB.Clement. Overexpression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastasis. Int J Cancer1997; 74: 426–32.
75. M.L.HautekeeteA.Geerts. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Archiv1997; 430: 195–207.
76. L.KlieveriO.FehresP.GriffiniC.J.Van NoordenW.M.Frederiks. Promotion of colon cancer metastases in rat liver by fish oil diet is not due to reduced stroma formation. Clin Exp Metastasis2000; 18: 371–7.
77. T.TeradaK.MakimotoN.TerayamaY.SuzukiY.Nakanuma. Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. J Hepatol1996; 24: 706–12.
78. C.EvenoP.HainaudA.RampanouP.BonninS.BakhoucheE.DupuyJ.O.ContreresM.Pocard. Proof of prometastatic niche induction by hepatic stellate cells. J Surg Res2015; 194: 496–504.
79. E.OlasoC.SaladoE.EgilegorV.GutierrezA.SantistebanP.Sancho-BruS.L.FriedmanF.Vidal-Vanaclocha. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology2003; 37: 674–85.
80. K.TauraS.De MinicisE.SekiE.HatanoK.IwaisakoC.H.OsterreicherY.KodamaK.MiuraI.IkaiS.UemotoD.A.Brenner. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology2008; 135: 1729–38.
81. T.TorimuraM.SataT.UenoM.KinR.TsujiK.SuzakuO.HashimotoH.SugawaraK.Tanikawa. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol1998; 29: 986–91.
82. T.TorimuraT.UenoM.KinR.HaradaE.TaniguchiT.NakamuraR.SakataO.HashimotoM.SakamotoR.KumashiroM.SataO.NakashimaH.YanoM.Kojiro. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol2004; 40: 799–807.
83. C.H.ChenL.M.KuoY.ChangW.WuC.GoldbachM.A.RossD.B.StolzL.ChenJ.J.FungL.LuS.Qian. In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology2006; 44: 1171–81.
84. C.CorpechotV.BarbuD.WendumN.KinnmanC.ReyR.PouponC.HoussetO.Rosmorduc. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology2002; 35: 1010–21.
85. D.SemelaA.DasD.LangerN.KangE.LeofV.Shah. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology2008; 135: 671–9.
86. W.WirzM.AntoineC.G.TagA.M.GressnerT.KorffC.HellerbrandP.Kiefer. Hepatic stellate cells display a functional vascular smooth muscle cell phenotype in a three-dimensional co-culture model with endothelial cells. Differ Res Biol Divers2008; 76: 784–94.
87. M.C.YuC.H.ChenX.LiangL.WangC.R.GandhiJ.J.FungL.LuS.Qian. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology2004; 40: 1312–21.
88. E.RoosK.P.DingemansI.V.Van de PavertM.A.Van den Bergh-Weerman. Mammary-carcinoma cells in mouse liver: infiltration of liver tissue and interaction with Kupffer cells. Br J Cancer1978; 38: 88–99.
89. E.RoosI.V.Van de PavertO.P.Middelkoop. Infiltration of tumour cells into cultures of isolated hepatocytes. J Cell Sci1981; 47: 385–97.
90. O.R.MookJ.van MarleR.JongesH.Vreeling-SindelarovaW.M.FrederiksC.J.Van Noorden. Interactions between colon cancer cells and hepatocytes in rats in relation to metastasis. J Cell Mol Med2008; 12: 2052–61.
91. O.R.MookJ.Van MarleH.Vreeling-SindelarovaR.JongesW.M.FrederiksC.J.Van Noorden. Visualization of early events in tumor formation of eGFP-transfected rat colon cancer cells in liver. Hepatology2003; 38: 295–304.
92. S.TabariesF.DupuyZ.DongA.MonastM.G.AnnisJ.SpicerL.E.FerriA.OmerogluM.BasikE.AmirM.ClemonsP.M.Siegel. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol2012; 32: 2979–91.
93. A.ElzagheidA.AlgarsR.BendardafH.LamlumR.RistamakiY.CollanK.SyrjanenS.Pyrhonen. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol2006; 12: 4304–9.
94. P.J.KowalskiM.A.RubinC.G.Kleer. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res2003; 5: R217–22.
95. C.C.YatesC.R.ShepardD.B.StolzA.Wells. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer2007; 96: 1246–52.
96. Y.ChaoQ.WuC.ShepardA.Wells. Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp Metastasis2012; 29: 39–50.
97. M.LiJ.M.AliottaJ.M.AsaraQ.WuM.S.DoonerL.D.TuckerA.WellsP.J.QuesenberryB.Ramratnam. Intercellular transfer of proteins as identified by stable isotope labeling of amino acids in cell culture. J Biol Chem2010; 285: 6285–97.
98. J.L.Luebke-WheelerG.NedredalL.YeeB.P.AmiotS.L.Nyberg. E-cadherin protects primary hepatocyte spheroids from cell death by a caspase-independent mechanism. Cell Transplant2009; 18: 1281–7.
99. D.G.HackamD.A.Redelmeier. Translation of research evidence from animals to humans. JAMA2006; 296: 1731–2.
100. J.MestasC.C.Hughes. Of mice and not men: differences between mouse and human immunology. J Immunol2004; 172: 2731–8.
101. A.FantozziG.Christofori. Mouse models of breast cancer metastasis. Breast Cancer Res2006; 8: 212–212.
102. C.KhannaK.Hunter. Modeling metastasis in vivo. Carcinogenesis2005; 26: 513–23.
103. B.A.Teicher. Tumor models for efficacy determination. Mol Cancer Ther2006; 5: 2435–43.
104. M.R.JunttilaF.J.de Sauvage. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature2013; 501: 346–54.
105. C.Y.SlaneyJ.RautelaB.S.Parker. The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res2013; 73: 5852–7.
106. J.P.Wikswo. The relevance and potential roles of microphysiological systems in biology and medicine. Exp Biol Med2014; 239: 1061–72.
107. L.G.GriffithA.WellsD.B.Stolz. Engineering liver. Hepatology2014; 60: 1426–34.
108. L.A.VernettiN.SenutovitchR.BoltzR.DeBiasioT.Ying ShunA.GoughD.L.Taylor. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med2016; 241: 101–14.
109. A.VillasanteG.Vunjak-Novakovic. Tissue-engineered models of human tumors for cancer research. Expert Opin Drug Discov2015; 10: 257–68.
110. S.E.WheelerJ.T.BorensteinA.M.ClarkM.R.EbrahimkhaniI.J.FoxL.GriffithW.InmanD.LauffenburgerT.NguyenV.C.PillaiR.Prantil-BaunD.B.StolzD.TaylorT.UlrichR.VenkataramananA.WellsC.Young. All-human microphysical model of metastasis therapy. Stem Cell Res Ther2013; 4: S11–S11.
111. K.H.BenamS.DauthB.HassellA.HerlandA.JainK.J.JangK.KaralisH.J.KimL.MacQueenR.MahmoodianS.MusahY.S.TorisawaA.D.van der MeerR.VillenaveM.YadidK.K.ParkerD.E.Ingber. Engineered in vitro disease models. Annu Rev Pathol2015; 10: 195–262.
112. N.SenutovitchL.VernettiR.BoltzR.DeBiasioA.GoughD.L.Taylor. Fluorescent protein biosensors applied to microphysiological systems. Exp Biol Med2015; 240: 795–808.
113. S.N.BhatiaD.E.Ingber. Microfluidic organs-on-chips. Nat Biotechnol2014; 32: 760–72.
114. S.S.BaleL.VernettiN.SenutovitchR.JindalM.HegdeA.GoughW.J.McCartyA.BakanA.BhushanT.Y.ShunI.GolbergR.DeBiasioO.B.UstaD.L.TaylorM.L.Yarmush. In vitro platforms for evaluating liver toxicity. Exp Biol Med2014; 239: 1180–91.
115. M.R.EbrahimkhaniJ.A.NeimanM.S.RaredonD.J.HughesL.G.Griffith. Bioreactor technologies to support liver function in vitro. Adv Drug Deliv Rev2014; 69–70: 132–57.
116. A.M.ClarkS.E.WheelerD.P.TaylorV.C.PillaiC.L.YoungR.Prantil-BaunT.NguyenD.B.StolzJ.T.BorensteinD.A.LauffenburgerR.VenkataramananL.G.GriffithA.Wells. A microphysiological system model of therapy for liver micrometastases. Exp Biol Med2014; 239: 1170–9.
117. K.DomanskyW.InmanJ.SerdyA.DashM.H.LimL.G.Griffith. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip2010; 10: 51–8.
118. C.YatesC.R.ShepardG.PapworthA.DashD.Beer StolzS.TannenbaumL.GriffithA.Wells. Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression. Adv Cancer Res2007; 97: 225–46.
119. S.E.WheelerA.M.ClarkD.P.TaylorC.L.YoungV.C.PillaiD.B.StolzR.VenkataramananD.LauffenburgerL.GriffithA.Wells. Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system. Br J Cancer2014; 111: 2342–50.
120. P.J.LeeP.J.HungL.P.Lee. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnol Bioeng2007; 97: 1340–6.
121. M.Y.ZhangP.J.LeeP.J.HungT.JohnsonL.P.LeeM.R.Mofrad. Microfluidic environment for high density hepatocyte culture. Biomed Microdevices2008; 10: 117–21.
122. P.LeeM.AllenP.HungChapter 14—Microfluidic hepatotoxicity platform A2—Bettinger, Christopher. In: (eds). Microfluidic cell culture systems, Oxford: William Andrew Publishing, 2013, pp. 341–55.
123. P.ChaoT.MaguireE.NovikK.C.ChengM.L.Yarmush. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol2009; 78: 625–32.
124. E.NovikT.J.MaguireP.ChaoK.C.ChengM.L.Yarmush. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol2010; 79: 1036–44.
125. P.D.KingM.C.Perry. Hepatotoxicity of chemotherapy. Oncologist2001; 6: 162–76.
126. J.T.ErlerV.M.Weaver. Three-dimensional context regulation of metastasis. Clin Exp Metastasis2009; 26: 35–49.